New Data For Abbott’s TRILIPIX(R) (fenofibric Acid) In Combination With Rosuvastatin Calcium Shows Improvement On Key Lipids For Cholesterol
Data from a new study showed that Abbott’s TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study’s primary endpoints. TRILIPIX 135 mg in combination with rosuvastatin calcium 5 mg significantly improved HDL cholesterol and triglycerides compared to rosuvastatin calcium 5 mg alone, and significantly improved LDL cholesterol compared to TRILIPIX 135 mg alone in patients with multiple lipid problems.